Navigation Links
Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs
Date:3/3/2008

context of the agreement

signed with Merck in March 2006

-- Euro 1.0 million received from Pfizer in April 2007, following the

review of an Investigational New Drug (IND) submission by the U.S. FDA

for a new experimental medicine for the treatment of glaucoma,

developed under the collaboration agreement signed between Pfizer and

NicOx in August 2004

-- Euro 5.0 million received from Merck in July 2007, following the

initiation of the first in a series of planned clinical studies for the

first selected drug candidate, in accordance with the companies' major

collaborative agreement to develop new nitric oxide-donating

antihypertensive agents using NicOx' proprietary technology

These amounts, received by the Company, result from a firm commitment by the other contracting party and have been immediately recognized in revenues because NicOx will not have continuing involvement in the future development of the compounds that are the subject of the collaboration agreements mentioned above.

During the financial year 2007, NicOx also recognized the following sums, initially recorded as prepaid income, in revenues:

-- Euro 2.5 million corresponding to the initial payment of euro 5.0

million from Pfizer as a technology exclusivity fee, following the

March 2006 agreement that granted Pfizer rights to an exclusive

worldwide license to develop and commercialize new drug candidates

using NicOx' proprietary technology in the field of ophthalmology

-- Euro 3.0 million corresponding to the funding of the research

collaboration, pursuant to the above referenced agreement signed with

Pfizer in March 2006.

-- Euro 3.8 million corresponding to the initial payment of euro 9.2

million received from Merck following the signature in March 2006 of a

collaboration agreement for new antih
'/>"/>

SOURCE NicOx S.A.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
2. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
3. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
4. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
5. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
6. Progen Pharmaceuticals Announces Fiscal 2007 Financial Results
7. Biopure Announces 2007 Third Quarter Financial Results
8. Xytis Names Gordon H. Busenbark as Chief Financial Officer
9. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
10. Pharmacopeia Announces Third Quarter 2007 Financial Results
11. Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 21, 2014  World Hemp Oil, an importer of ... they are now offering legal, organic oil with high ... strains grown in medical marijuana states. People suffering from ... as Parkinson,s, MS, and spinal cord injury, no longer ... because imported CBD Oil Is legal in all states. ...
(Date:11/21/2014)... , Nov. 21, 2014 ... European Medicines Agency (EMA) has granted Orphan ... lead product candidate, for the treatment of ... rare, severely disabling genetic disease characterized by ... (flare-ups) and new abnormal bone formation. This ...
(Date:11/21/2014)... BRYDGES, Ontario , Nov. 20, 2014 /PRNewswire/ ... monitor mounting solutions and reading room environment guidance, ... their newest musculoskeletal radiology reading room, which may ... room designs at Penn Medicine. ... by the American College of Radiology,s Imaging 3.0 ...
Breaking Medicine Technology:New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 2New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 3Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 2Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 3RedRick Technologies Helps Penn Radiology Implement New Radiology Reading Room Concepts 2RedRick Technologies Helps Penn Radiology Implement New Radiology Reading Room Concepts 3
... Jan. 2 Amicus Therapeutics,Inc. (Nasdaq: FOLD ), ... Officer, will present a corporate update at the 26th ... January 7,2008 at 11:30 am (Pacific Standard Time) at ... be webcast live and may be accessed by visiting,Amicus, ...
... Inc. (Nasdaq: ALTH ) today announced that ... pre-specified 65-patient,safety review of data from the Company,s ... patients with relapsed or refractory peripheral,T-cell lymphoma (PTCL), ... the,protocol. This interim assessment was based upon an ...
Cached Medicine Technology:Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference 2Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference 3Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma 2Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma 3Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma 4Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma 5
(Date:11/23/2014)... To show thanks to new and old ... white evening dresses for weddings. Customers who need ... iFitDress.com is a distinguished dress manufacturer, and it is among ... customers for a very long time. The CEO of this ... will be able to buy not only a beautiful dress, ...
(Date:11/23/2014)... Washington, DC (PRWEB) November 23, 2014 ... monthly Tech Report , which features the latest ... a technology expert and reporter for NewsWatch, conducted the ... cameras are unique and powerful options in the car ... is rising and it can be hard to find ...
(Date:11/23/2014)... Utah (PRWEB) November 23, 2014 ... insurance reimbursement for small businesses, announced their new ... The End of Employer-Provided Health Insurance. ... is the greatest financial risk facing most American ... U.S. employers, small and large, when it comes ...
(Date:11/22/2014)... Recently, UWDress.com, a successful wedding dress shop, ... attire in order to prepare for the wedding season. ... 70% off. , UWDress.com is a reliable company that ... especially the new items -- formal wedding guest attire. This ... market, including superstar and princess. As one of the leading ...
(Date:11/22/2014)... 22, 2014 Setria® Glutathione is ... approved it for use “as a therapeutically active ... within the Therapeutic Goods (Listing) Notice 2014 (No. ... Hakko’s Setria® Glutathione will be exclusivity distributed in ... sources and imports fine chemicals to Australian manufacturers. ...
Breaking Medicine News(10 mins):Health News:iFitDress.com: Wonderful White Evening Dresses Now Available 2Health News:A Leader in Front and Rear Facing In-Car Cameras was Featured on NewsWatch Television on October 30, 2014 2Health News:Zane Benefits, Inc. Announces New Webinar on The End of Employer-Provided Health Insurance Now Available On-Demand! 2Health News:Formal Wedding Guest Attire Added to UWDress.com 2Health News:Setria® Glutathione Now Available in Australia 2Health News:Setria® Glutathione Now Available in Australia 3
... to Attend Conference, LAS VEGAS, Sept. 10 ... http://www.skinvisible.com ), the developers,of Invisicare(R), a proprietary ... announced that Mr. Terry Howlett,President & CEO, will ... & Co.,Investor Summit on September 18, 2007 at ...
... Montague and Wolf Haldenstein Obtain Third-Largest Settlement,in Securities ... PHILADELPHIA, Sept. 10 Judge Morris E.,Lasker ... of Massachusetts has,granted final approval of a $52.5 ... actions against Sepracor Inc., a,Massachusetts-based pharmaceutical company (Nasdaq: ...
... a protein best known as a common marker of inflammation ... The research, published by Cell Press in the September issue ... a potential target for cancer treatment. , CRP is a ... during the process of inflammation in response to the inflammatory ...
... eating fattening foods and not getting enough exercise are all ... disease more so if you have a family history. ... women dont change these habits as often as men, even ... reporting in the September issue of the American Heart ...
... Expansion of Services Now Ranges From Birth Through ... The Exceptional,Children,s Foundation (ECF) announced today that it ... one of California,s largest and most,unique nonprofit organizations ... disabilities. As a result of the,merger, ECF becomes ...
... Abbott (NYSE:,ABT) -- the global health care company ... Index and the Dow Jones Sustainability North America,Index ... Abbott,s,continued leadership in business, environmental and social performance. ... approach to business," said,Miles D. White, chairman and ...
Cached Medicine News:Health News:Skinvisible to Present at Merriman Curhan Ford & Co.'s Investor Summit 2007 2Health News:$52.5 Million Settlement Against Sepracor Inc. Approved 2Health News:Human C-reactive protein regulates myeloma tumor cell growth and survival 2Health News:Women less likely than men to change habits that increase heart disease risk 2Health News:Exceptional Children's Foundation Merger with Kayne Eras Center Creates One of State's Most Comprehensive Nonprofits Serving the Disabled 2Health News:Exceptional Children's Foundation Merger with Kayne Eras Center Creates One of State's Most Comprehensive Nonprofits Serving the Disabled 3Health News:Dow Jones Sustainability Index Again Recognizes Abbott for Continued Leadership in Business, Environmental and Social Performance 2
... Available As One Unit, Shaped Like A Fan, ... Of A Phaco Incision. The Gauges Start At ... Up To With 100-Micron Increments. The ... Information As To The Preoperative And Postoperative Incision ...
... Unique Reversible Speculums Designed To ... By Flipping The Speculums Over, Allowing ... Palpebral Fissures To The Widest Possible ... Providing Unobstructed Around-The-Clock Access To The ...
... A Micrometer Handle, Designed To Dial An ... Single Footplate Allows Maximum Visibility, With Titanium ... Blade Tracks Better In Tissue, And Can ... Making A Paracentesis., ,Reusable, Autoclaveable, Made In The ...
2.5V Halogen source, fiber-optic delivery, 2.5X magnification....
Medicine Products: